Antiviral Compounds from Myxobacteria
AbstractViral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites. View Full-Text
Share & Cite This Article
Mulwa, L.S.; Stadler, M. Antiviral Compounds from Myxobacteria. Microorganisms 2018, 6, 73.
Mulwa LS, Stadler M. Antiviral Compounds from Myxobacteria. Microorganisms. 2018; 6(3):73.Chicago/Turabian Style
Mulwa, Lucky S.; Stadler, Marc. 2018. "Antiviral Compounds from Myxobacteria." Microorganisms 6, no. 3: 73.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.